Digital health veteran to join expanding global team
MELBOURNE, Australia, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader in digital health technologies that address sub-optimal medication use in chronic disease, has appointed Scott Fleming as Senior Vice President of Business Development, Europe with immediate effect. John Tarplee stepped down from the role at the end of December 2016 to pursue a new venture.
Mr. Fleming is a founding member of the digital drug delivery movement. With 25 years’ sector experience covering strategy, device development, sales and marketing and big pharma, he brings valuable commercial knowledge and will continue to develop Adherium’s partnerships within the key European markets.
After gaining an interest in drug delivery, particularly inhaled and needle-free delivery, at PA Consulting in the US, Mr. Fleming co-founded MicroDose Therapeutx (MicroDose) in 1997, developing the first totally digital piezo driven dry powder inhaler which was then licensed to big pharma. During his tenure as Sr. Vice President, he led MicroDose’s strategy and executed numerous licensing and development collaborations with Bristol-Myers Squibb Company, Novartis International AG, Merck & Co. and Gilead Sciences Inc., among others, for respiratory programs using the digital inhaler and associated in-house molecules.
Mr. Fleming engineered the sale of MicroDose to Teva Pharmaceutical Industries Ltd (Teva) in 2013, and subsequently took on a key role as the Global Brand Lead for eConnectivity of Teva’s respiratory franchise based in Amsterdam, NL. Mr. Fleming was responsible for the commercial and branding strategy for eConnectivity of Teva’s branded inhaler products, including the acquired MicroDose technology, supporting the development and future launches of these products.
Mr. Fleming is a listed inventor on numerous patents and his research in the field of digital drug delivery has been published in peer reviewed journals including Respiratory Drug Delivery and Current Opinion in Investigational Drugs. He has also presented data at sector conferences including Respiratory Drug Delivery, Drug Delivery to the Lungs and Partnership Opportunities in Drug Delivery.
Mr. Fleming will be based in Amsterdam, Netherlands, where Adherium’s European operations will now be based and will continue to develop Adherium’s partnerships within the key European market and beyond.
Garth Sutherland, CEO of Adherium said:
“Bringing a pioneer of the digital health movement into our business is an exciting development as we continue to build our commercial capabilities, particularly in Europe. Scott’s 25 years’ experience in the field, combined with Adherium’s leading expertise will ensure a compelling proposition for partners and customers.”
Scott Fleming added:
“Having first collaborated with Adherium nine years ago, working to enable data capture to the cloud, it is great to now be joining the team. I have watched Adherium’s technology grow to play a vital role providing key clinical data proofs for the digital drug delivery industry. I look forward to using my experience in this space to build on Adherium’s capabilities, reaching more patients and improving adherence and outcomes.”
Adherium (ASX:ADR) is an Australian Securities Exchange listed company which develops, manufactures and supplies digital health technologies which address sub-optimal medication use and improve health outcomes in chronic disease.
Adherium operates globally from bases in the USA, Europe and Australasia.
Adherium is a provider of digital health solutions to patients, pharmaceutical companies, healthcare providers and contract research organizations. The Company’s proprietary Smartinhaler™ platform has been independently proven to improve medication adherence and health outcomes for patients with chronic respiratory disease. Adherium has the broadest range of "smart" medication sensors for respiratory medications globally.
The Smartinhaler™ platform has so far been used in more than 65 projects (clinical, device validation or other) and has been referenced in 56 peer reviewed journal articles. Clinical outcomes data has proven that the Smartinhaler™ platform can improve adherence by up to 59% in adults and 180% in children and reduce severe episodes by 60% in adults, leading to improved quality-of-life and demonstrating a substantial gain over current best practice treatment. The Company has received FDA 510(k) notifications for clearance to market and CE Marks for its devices and software, which allows it to sell these devices into international markets.
|Julia Chambers||James Hattersley||Scott Fleming|
|Head of Corporate Development||Senior Vice President||Senior Vice President|
|M: +64 27 807 8153||Business Development||Business Development|
|E: firstname.lastname@example.org||North America||Europe|
|M: +1 610 955 5886||M: +31 646 876 989|
|E: email@example.com||E: firstname.lastname@example.org|
|Australia and New Zealand||North America||Europe|
|Rudi Michelson||Erich Sandoval||Sue Charles/Rozi Morris|
|Monsoon Communications||Lazar Partners||Instinctif Partners|
|D: +61 3 9620 3333||D: +1 213-908-6226||D: +44 20 7457 2020|
|E: email@example.com||E: firstname.lastname@example.org||E: email@example.com|